This is a working overview of acylated peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-17 and is reviewed periodically as new material appears.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Barq's Cream Soda – clear Big 8 Cream Soda – pink and clear Cott Cream Soda Crush – pink and clear Fanta Jones Soda Kiri Cream Soda – clear Life Brand The Pop Shoppe – also markets a vodka-based alcoholic version President's Choice - clear Walmart Canada – US-style vanilla flavor Some American brands are available in Canada as imports.
== Coordination chemistry and applications == The conjugate base of NTA is a tripodal tetradentate trianionic ligand, forming coordination compounds with a variety of metal ions. Like EDTA, its sodium salt is used for water softening to remove Ca2+. For this purpose, NTA is a replacement for triphosphate, which once was widely used in detergents, and cleansers, but can cause eutrophication of lakes. In one application, sodium NTA removes Cr, Cu, and As from wood that had been treated with chromated copper arsenate.
The Raleigh area has hosted the Professional Golfers' Association (PGA) Nationwide Tour Rex Hospital Open since 1994, with the current location of play at Raleigh's Country Club at Wakefield Plantation. Nearby Prestonwood Country Club hosts the PGA SAS Championship every fall.
=== Lifestyle === Regular exercise is recommended as both safe and effective to maintain muscle strength and overall physical function. Physical activity is beneficial for people with rheumatoid arthritis who experience fatigue, although there was little to no evidence to suggest that exercise may have an impact on physical function in the long term, a study found that carefully dosed exercise has shown significant improvements in patients with RA. Physical activity increases the production of synovial fluid, which lubricates the joints and reduces friction. Moderate effects have been found for aerobic exercises and resistance training on cardiovascular fitness and muscle strength in RA. Furthermore, physical activity had no detrimental side effects like increased disease activity in any exercise dimension. It is uncertain if eating or avoiding specific foods or other specific dietary measures help improve symptoms, but several studies have shown that high-vegetable diets improve RA symptoms, whereas high-meat diets make symptoms worse. Occupational therapy has a positive role to play in improving functional ability in people with rheumatoid arthritis. Weak evidence supports the use of wax baths (thermotherapy) to treat arthritis in the hands. Educational approaches that inform people about tools and strategies available to help them cope with rheumatoid arthritis may improve a person's psychological status and level of depression in the short term.
In another study, the combination of positively charged peptide amphiphiles and negatively charged long biopolymers led to the formation of hierarchically ordered membranes. When the two solutions are brought into contact, electrostatic complexation between the components of each solution creates a diffusion barrier that prevents the mixing of the solutions. Over time, an osmotic pressure difference drives the reptation of polymer chains through the diffusion barrier into the peptide amphiphile compartment, leading to the formation of fibers perpendicular to the interface that grow over time. These materials can be made in the form of flat membranes or as spherical sacs by dropping one solution into the other. These materials are robust enough to handle mechanically and a range of mechanical properties can be accessed by altering growth conditions and time. They can incorporate bioactive peptide amphiphiles, encapsulate cells and biomolecules, and are biocompatible and biodegradable.
Sources: en.wikipedia.org
Acquired generalized lipodystrophy (Lawrence syndrome, Lawrence–Seip syndrome) Adiposis dolorosa (Dercum's disease) Alpha-1 antitrypsin deficiency panniculitis (alpha1-protease deficiency panniculitis, alpha1-proteinase deficiency panniculitis) Atrophic connective tissue panniculitis Barraquer–Simons syndrome (acquired partial lipodystrophy, cephalothoracic lipodystrophy, progressive lipodystrophy) Benign symmetric lipomatosis (benign symmetric lipomatosis of Launois–Bensaude, Madelung's disease) Centrifugal abdominal lipodystrophy (centrifugal lipodystrophy, lipodystrophia centrifugalis abdominalis infantalis) Chronic erythema nodosum (erythema nodosum migrans, subacute migratory panniculitis of Vilanova and Piñol, subacute nodular migratory panniculitis) Cold panniculitis (popsicle panniculitis) Congenital generalized lipodystrophy (Berardinelli–Seip syndrome) Cytophagic histiocytic panniculitis Drug-induced lipodystrophy Factitial panniculitis Familial partial lipodystrophy (Köbberling–Dunnigan syndrome) Gouty panniculitis Hemihyperplasia–multiple lipomatosis syndrome HIV-associated lipodystrophy Involutional lipoatrophy Lipoatrophia annularis (Ferreira–Marques lipoatrophia) Lipoatrophia semicircularis (semicircular lipoatrophy) Lipodermatosclerosis (chronic panniculitis with lipomembranous changes, hypodermitis sclerodermiformis, sclerosing panniculitis, stasis panniculitis) Lipohypertrophy Localized lipodystrophy Neutrophilic lobular panniculitis Nodular vasculitis Non-progressive late-onset linear hemifacial lipoatrophy Pancreatic panniculitis (enzymatic panniculitis, pancreatic fat necrosis, subcutaneous fat necrosis) Poland's syndrome Post-steroid panniculitis Sclerema neonatorum Sclerosing lipogranuloma (paraffinoma) Septal panniculitis Subcutaneous fat necrosis of the newborn Traumatic panniculitis Tumor lysis syndrome Weber–Christian disease (relapsing febrile nonsuppurative panniculitis)
== References == This article incorporates text from a publication now in the public domain: Chisholm, Hugh, ed. (1911). "Chevreul, Michel Eugène". Encyclopædia Britannica (11th ed.). Cambridge University Press.
13,000, 30 October 2006 – The SENSEX on 30 October 2006 crossed 13,000 mark for the first time, touching a peak of 13,039.36, before closing at 13,024.26 points. It took 135 days to reach 13,000 from 12,000, and 124 days to reach 13,000 from 12,500. 14,000, 5 December 2006 – The SENSEX on 5 December 2006 crossed 14,000 mark for the first time, after opening the day with a peak of 14,028 at 9.58 am (IST).
=== Metalloproteins and inorganic cofactors === Metalloproteins—in which the active site is a transition metal ion (or metal-sulfide cluster) often coordinated by sulfur atoms of cysteine residues—are essential components of enzymes involved in electron transfer processes. Examples include plastocyanin (Cu2+) and nitrous oxide reductase (Cu–S). The function of these enzymes is dependent on the fact that the transition metal ion can undergo redox reactions. Other examples include many zinc proteins, as well as iron–sulfur clusters. Most pervasive are the ferrodoxins, which serve as electron shuttles in cells. In bacteria, the important nitrogenase enzymes contain an Fe–Mo–S cluster and is a catalyst that performs the important function of nitrogen fixation, converting atmospheric nitrogen to ammonia that can be used by microorganisms and plants to make proteins, DNA, RNA, alkaloids, and the other organic nitrogen compounds necessary for life. Sulfur is also present in molybdenum cofactor.
Transfer ribonucleic acid (tRNA), formerly referred to as soluble ribonucleic acid (sRNA), is an adaptor molecule composed of RNA, typically 76 to 90 nucleotides in length (in eukaryotes). In a cell, it provides the physical link between the genetic code in messenger RNA (mRNA) and the amino acid sequence of proteins, carrying the correct sequence of amino acids to be combined by the protein-synthesizing machinery, the ribosome. Each three-nucleotide codon in mRNA is complemented by a three-nucleotide anticodon in tRNA. As such, tRNAs are a necessary component of translation, the biological synthesis of new proteins in accordance with the genetic code.
Sources: en.wikipedia.org
During Alice in Chains' hiatus, reports of Staley's addiction began to gain widespread circulation in fan and media communities, in part due to changes in his physical condition brought on by prolonged heroin abuse. Alice in Chains regrouped to record Alice in Chains, sometimes referred to as "Tripod" due to the cover featuring a three-legged dog, which was released in November 1995. The album debuted at the top of the U.S. charts, and has since been awarded—along with Facelift and Jar of Flies—double platinum status. With the exceptions of "Grind", "Heaven Beside You", and "Over Now", the lyrics were all written by Staley, making this album his greatest lyrical contribution to the band's catalog. To accompany the album, the band released a home video, The Nona Tapes, but the band lapsed again, failing to complete tours planned in support of the album. When asked about the frustration of not touring to support the record, Cantrell provided some insight into how Staley's addictions led to tensions within the band: "Very frustrating, but we stuck it out. We rode the good times together, and we stuck together through the hard times. We never stabbed each other in the back and spilled our guts and [did] that kind of bullshit that you see happen a lot." "Drugs worked for me for years", Staley told Rolling Stone in February 1996, "and now they're turning against me, now I'm walking through hell and this sucks. I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high.
== General characteristics == Pseudomonas fluorescens has multiple flagella, an extremely versatile metabolism, and can be found in the soil and in water. It is an obligate aerobe, but certain strains are capable of using nitrate instead of oxygen as a final electron acceptor during cellular respiration. Optimal temperatures for growth of P. fluorescens are 25–30°C. It tests positive for the oxidase test, and is also a nonsaccharolytic bacterial species. Heat-stable lipases and proteases are produced by P. fluorescens and other similar pseudomonads. These enzymes cause milk to spoil, by causing bitterness, casein breakdown, and ropiness due to production of slime and coagulation of proteins.
== Confusion with other wheats == Especially in the context of descriptions of ancient cultures, the English word spelt has sometimes been used for grains that were not T. spelta, but other species of hulled wheat such as T. dicoccum (emmer) or T. monococcum (einkorn, also known as "little spelt", in French petit épeautre). This confusion may arise either from mistranslation of words found in other languages that can denote hulled wheat in general (such as Italian farro, which can denote any of emmer, spelt or einkorn; spelt is sometimes distinguished as farro grande ('large farro'), emmer as farro medio ('medium farro'), and einkorn as farro piccolo ('little farro')), or changing opinions about which actual species of wheat are described in texts written in ancient languages. Thus, the meaning of the ancient Greek word ζειά (zeiá) or ζέα is either uncertain or vague, and has been argued to denote einkorn or emmer rather than spelt. The ancient Roman grain denoted by the Latin word far, although often translated as 'spelt', was in fact emmer.
Although this method has only a limited efficacy, unlike small-molecular chelators (deferasirox, deferiprone, or deferoxamine), such an approach may have only minor side effects in sub-chronic studies. Interestingly, the simultaneous chelation of Fe2+ and Fe3+ increases the treatment efficacy.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.